{
  "company": {
    "ticker": "VRTX",
    "name": "Vertex Pharmaceuticals Inc.",
    "category": [
      "Biotech"
    ],
    "sector": "Healthcare",
    "subCategory": "Biotech",
    "cik": "0000875320"
  },
  "reports": [
    {
      "filing": {
        "accessionNumber": "0000875320-25-000232",
        "filingDate": "2025-11-04",
        "reportDate": "2025-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/vrtx-20250930.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 3076.4,
        "netIncome": 1082.9,
        "operatingCashFlow": 3133.4,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 182,
        "marketShareMention": "Collectively, our five medicines are being used to treat more than three quarters of the approximately 94,000 people with CF in the U.S., Europe, Australia, and Canada",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United_States": 64.2,
          "Europe": 27.2,
          "Other": 8.6
        },
        "capexAmount": 288.2,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics collaboration",
          "Zai Lab povetacicept licensing in China",
          "Ono Pharmaceuticals povetacicept licensing in Japan/South Korea",
          "CRISPR Therapeutics",
          "Entrada Therapeutics",
          "Zai Lab",
          "Ono Pharmaceuticals"
        ],
        "supplyChainStatus": "unknown",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex reported strong Q3 2025 performance with product revenues growing to $3.1 billion, driven by continued demand for TRIKAFTA/KAFTRIO and early contributions from new product launches like JOURNAVX. The company continues to expand its market leadership in cystic fibrosis and make progress in sickle cell disease and acute pain markets.",
        "keyQuotes": [
          "We expect that the number of people with CF taking our medicines will continue to grow through new approvals and reimbursement agreements",
          "Globally, since launch through September 30, 2025, approximately 165 people with SCD or TDT have had their first cell collection for CASGEVY"
        ],
        "marketData": {}
      },
      "quarter": "Q3 2025",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2025,
        "fiscalQuarter": 3,
        "fiscalYear": 2025,
        "quarter": "Q3 2025",
        "reportDate": "2025-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-25-000216",
        "filingDate": "2025-08-05",
        "reportDate": "2025-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/vrtx-20250630.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "raised",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "stable",
        "revenue": 2944,
        "netIncome": 1032.9,
        "operatingCashFlow": 1892,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 146.9,
        "marketShareMention": "Collectively, our five medicines are being used to treat more than three quarters of the approximately 94,000 people with CF in the U.S., Europe, Australia, and Canada",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United States": 62.1,
          "Europe": 30.9,
          "Other": 7
        },
        "capexAmount": 186.4,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics AG",
          "Moderna, Inc.",
          "Zai Lab Limited",
          "Ono Pharmaceuticals Co., Ltd.",
          "CRISPR Therapeutics",
          "Ono Pharmaceuticals",
          "Entrada Therapeutics",
          "Alphine Immune Sciences"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong quarterly performance with product revenues of $2.9B, driven by continued demand for TRIKAFTA/KAFTRIO and early contributions from new product launches. The company is expanding across multiple therapeutic areas including cystic fibrosis, sickle cell disease, and acute pain.",
        "keyQuotes": [
          "We expect that the number of people with CF taking our medicines will continue to grow through new approvals and reimbursement agreements",
          "We have begun our commercial launch of JOURNAVX in the U.S. for eligible adults"
        ],
        "marketData": {}
      },
      "quarter": "Q2 2025",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2025,
        "fiscalQuarter": 2,
        "fiscalYear": 2025,
        "quarter": "Q2 2025",
        "reportDate": "2025-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-25-000192",
        "filingDate": "2025-05-06",
        "reportDate": "2025-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/vrtx-20250331.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "stable",
        "revenue": 2770.2,
        "netIncome": 646.3,
        "operatingCashFlow": 818.9,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 228.4,
        "marketShareMention": "Five medicines treating nearly three quarters of CF patients in US, Europe, Australia, Canada",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United_States": 59.9,
          "Europe": 29.9,
          "Other": 10.2
        },
        "capexAmount": 40.7,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics collaboration for CASGEVY",
          "Moderna collaboration for VX-522 CFTR mRNA therapy",
          "Entrada Therapeutics license for myotonic dystrophy program",
          "Zai Lab collaboration for povetacicept in Asia"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong Q1 2025 results driven by continued performance of TRIKAFTA/KAFTRIO and initial contributions from newly launched ALYFTREK. The company continues to expand its CF portfolio while advancing promising pipeline programs in pain, diabetes, and kidney diseases.",
        "keyQuotes": [
          "We expect to grow our CF business by increasing the number of people with CF who are eligible and able to receive our medicines.",
          "We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases utilizing a range of modalities."
        ],
        "marketData": {}
      },
      "quarter": "Q1 2025",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2025,
        "fiscalQuarter": 1,
        "fiscalYear": 2025,
        "quarter": "Q1 2025",
        "reportDate": "2025-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-25-000053",
        "filingDate": "2025-02-13",
        "reportDate": "2024-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/vrtx-20241231.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 1691.8999999999996,
        "netIncome": 4648.6,
        "operatingCashFlow": null,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Multiple competitive therapies emerging in key therapeutic areas like cystic fibrosis, sickle cell disease, and others",
        "customerConcentration": null,
        "geographicBreakdown": null,
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR",
          "Moderna",
          "Entrada",
          "Zai",
          "CRISPR Therapeutics",
          "Zai Lab",
          "Entrada Therapeutics",
          "Editas Medicine"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [
          "Increasing drug pricing regulations",
          "Complex cell and gene therapy approval processes",
          "Government pricing program changes"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Vertex maintains a strong position in rare disease therapeutics, particularly in cystic fibrosis, with significant revenue from CF medicines. The company faces ongoing challenges related to drug pricing regulations and complex regulatory landscapes for cell and gene therapies.",
        "keyQuotes": [
          "Our business depends upon the successful development and commercialization of product candidates",
          "Substantially all of our net product revenues have been derived from the sale of our CF medicines over the last several years"
        ],
        "marketData": {}
      },
      "quarter": "Q4 2024",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2024,
        "fiscalQuarter": 4,
        "fiscalYear": 2024,
        "quarter": "Q4 2024",
        "reportDate": "2024-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-24-000223",
        "filingDate": "2024-11-05",
        "reportDate": "2024-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/vrtx-20240930.htm"
      },
      "insights": {
        "guidanceTone": "confident",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2771.9,
        "netIncome": 1045.4,
        "operatingCashFlow": -1077.2,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 220,
        "marketShareMention": "Nearly 3/4 of ~92,000 CF patients in North America, Europe, Australia",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United States": 61.8,
          "Europe": 30.6,
          "Other": 7.6
        },
        "capexAmount": 205.1,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics (CASGEVY)",
          "Moderna (CF mRNA therapy)",
          "Alpine Immune Sciences (povetacicept acquisition)"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong quarterly performance driven by continued growth of TRIKAFTA/KAFTRIO and successful launch of CASGEVY. The company is expanding its pipeline across multiple therapeutic areas including cystic fibrosis, sickle cell disease, and pain management.",
        "keyQuotes": [
          "We are pursuing messenger ribonucleic acid (mRNA) and genetic therapies for people with CF",
          "We estimate approximately 35,000 people with severe SCD or TDT could be eligible for CASGEVY in the U.S. and Europe",
          "We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases"
        ],
        "marketData": {}
      },
      "quarter": "Q3 2024",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2024,
        "fiscalQuarter": 3,
        "fiscalYear": 2024,
        "quarter": "Q3 2024",
        "reportDate": "2024-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-24-000198",
        "filingDate": "2024-08-02",
        "reportDate": "2024-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/vrtx-20240630.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "not_provided",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2645.6,
        "netIncome": -3593.6,
        "operatingCashFlow": -2447,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 128.3,
        "marketShareMention": "nearly three quarters of approximately 92,000 people with CF in North America, Europe, and Australia",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United States": 61,
          "Europe": 30.5,
          "Other": 8.5
        },
        "capexAmount": 137.4,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics (gene editing)",
          "Moderna (CF mRNA therapy)",
          "Alpine Immune Sciences (acquired)"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Vertex reported strong CF product revenues driven by TRIKAFTA, while investing heavily in pipeline expansion through strategic acquisitions like Alpine Immune Sciences. The company faces near-term potential launches in CF and pain therapeutics while maintaining a diverse research portfolio across multiple disease areas.",
        "keyQuotes": [
          "We are evaluating our CF medicines in additional patient populations, including younger children",
          "We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases",
          "We estimate approximately 35,000 people with severe SCD or TDT could be eligible for CASGEVY in the U.S. and Europe"
        ],
        "marketData": {}
      },
      "quarter": "Q2 2024",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2024,
        "fiscalQuarter": 2,
        "fiscalYear": 2024,
        "quarter": "Q2 2024",
        "reportDate": "2024-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-24-000139",
        "filingDate": "2024-05-07",
        "reportDate": "2024-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/vrtx-20240331.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "raised",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2690.6,
        "netIncome": 1099.6,
        "operatingCashFlow": 1306.6,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Nearly three quarters of approximately 92,000 people with CF in North America, Europe, and Australia treated with Vertex CF medicines",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United States": 56.5,
          "Europe": 36,
          "Other": 7.5
        },
        "capexAmount": 68.4,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics collaboration for gene-editing therapies",
          "Moderna collaboration for mRNA CF therapy",
          "Entrada Therapeutics collaboration for myotonic dystrophy therapy",
          "Alpine Immune Sciences acquisition agreement"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong Q1 2024 performance driven by continued growth of its CF franchise and initial commercialization of CASGEVY. The company maintains a robust pipeline across multiple therapeutic areas and continues to invest in innovative research and external collaborations.",
        "keyQuotes": [
          "We expect to grow our CF business with continued uptake, label expansions, and growth in the number of people living with CF",
          "Our strategy is to combine transformative advances in the understanding of causal human biology and the science of therapeutics to discover and develop innovative medicines"
        ],
        "marketData": {}
      },
      "quarter": "Q1 2024",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2024,
        "fiscalQuarter": 1,
        "fiscalYear": 2024,
        "quarter": "Q1 2024",
        "reportDate": "2024-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-24-000062",
        "filingDate": "2024-02-15",
        "reportDate": "2023-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/vrtx-20231231.htm"
      },
      "insights": {
        "guidanceTone": "confident",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 1561.5,
        "netIncome": -455.8000000000002,
        "operatingCashFlow": null,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Vertex remains a leader in cystic fibrosis treatments and is expanding into cell and gene therapies",
        "customerConcentration": null,
        "geographicBreakdown": null,
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "Lonza (for T1D cell therapy manufacturing)"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [
          "Evolving cell and gene therapy regulatory landscape",
          "Potential drug pricing regulations",
          "Complex approval processes for advanced therapies"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex continues to demonstrate strong performance in cystic fibrosis while expanding into cell and gene therapies, particularly with CASGEVY for sickle cell disease and thalassemia. The company is investing in manufacturing capabilities and navigating a complex regulatory environment.",
        "keyQuotes": [
          "We are focused on ensuring the stability of the supply chains for our current products",
          "We continue to invest significant resources in expanding and strengthening our manufacturing supplies, infrastructure and capabilities"
        ],
        "marketData": {}
      },
      "quarter": "Q4 2023",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2023,
        "fiscalQuarter": 4,
        "fiscalYear": 2023,
        "quarter": "Q4 2023",
        "reportDate": "2023-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-23-000031",
        "filingDate": "2023-11-07",
        "reportDate": "2023-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/vrtx-20230930.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "raised",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2483.5,
        "netIncome": 1035.3,
        "operatingCashFlow": 3302.7,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 157.1,
        "marketShareMention": "Collectively, our four medicines are being used to treat more than two-thirds of the approximately 88,000 people with CF in North America, Europe, and Australia",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United States": 62.6,
          "Europe": 30.9,
          "Other": 6.5
        },
        "capexAmount": 142.3,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics collaboration on gene-editing therapies",
          "Moderna collaboration on CFTR mRNA therapeutic",
          "Entrada Therapeutics collaboration on myotonic dystrophy"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex continues to demonstrate strong performance in its cystic fibrosis franchise, with Q3 revenue growing to $2.5 billion. The company is advancing multiple pipeline programs across various disease areas, with near-term potential launches in sickle cell disease, beta thalassemia, and acute pain.",
        "keyQuotes": [
          "We are preparing for near-term launches of potential new products in sickle cell disease, beta thalassemia, CF and acute pain",
          "We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases utilizing a range of modalities"
        ],
        "marketData": {}
      },
      "quarter": "Q3 2023",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2023,
        "fiscalQuarter": 3,
        "fiscalYear": 2023,
        "quarter": "Q3 2023",
        "reportDate": "2023-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-23-000021",
        "filingDate": "2023-08-02",
        "reportDate": "2023-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/vrtx-20230630.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2493.2,
        "netIncome": 915.7,
        "operatingCashFlow": 2034.3,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 179.1,
        "marketShareMention": "CF medicines now treat more than two-thirds of approximately 88,000 people with CF in North America, Europe, and Australia",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United States": 60.5,
          "Europe": 32.1,
          "Other": 7.4
        },
        "capexAmount": 101.7,
        "capexGrowth": null,
        "partnerships": [
          "Moderna (CFTR mRNA therapy)",
          "CRISPR Therapeutics (gene editing)",
          "Entrada Therapeutics (myotonic dystrophy)",
          "Lonza (cell therapy manufacturing)"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong Q2 results with $2.5B in revenues, driven by continued TRIKAFTA/KAFTRIO uptake across international markets. The company is preparing for multiple potential near-term product launches in sickle cell disease, beta thalassemia, and acute pain, while maintaining a diverse pipeline across multiple therapeutic areas.",
        "keyQuotes": [
          "We are preparing for near-term launches of potential new products in sickle cell disease, beta thalassemia, CF and acute pain.",
          "We continue to advance a diversified pipeline of potentially transformative small molecule, mRNA, cell and genetic therapies aimed at treating serious diseases."
        ],
        "marketData": {}
      },
      "quarter": "Q2 2023",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2023,
        "fiscalQuarter": 2,
        "fiscalYear": 2023,
        "quarter": "Q2 2023",
        "reportDate": "2023-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-23-000012",
        "filingDate": "2023-05-02",
        "reportDate": "2023-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/vrtx-20230331.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "raised",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2374.8,
        "netIncome": 699.8,
        "operatingCashFlow": 899.9,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 236.4,
        "marketShareMention": "Vertex medicines are being used to treat more than two-thirds of approximately 88,000 people with CF in North America, Europe, and Australia",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United States": 59.1,
          "Europe": 34,
          "Other": 6.9
        },
        "capexAmount": 42.1,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics collaboration for gene-editing therapies",
          "Moderna collaboration for CFTR mRNA therapeutic",
          "Entrada Therapeutics collaboration for DM1 therapeutics"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong Q1 2023 financial results with $2.4B in product revenues, driven by continued uptake of TRIKAFTA/KAFTRIO. The company is advancing multiple pipeline programs across cystic fibrosis, sickle cell disease, beta thalassemia, and other serious diseases while maintaining a robust cash position of $11.5B.",
        "keyQuotes": [
          "We are preparing for near-term launches of potential new products in sickle cell disease, beta thalassemia, CF and acute pain.",
          "We continue to advance a pipeline of potentially transformative small molecule, mRNA, and cell and genetic therapies aimed at treating serious diseases."
        ],
        "marketData": {}
      },
      "quarter": "Q1 2023",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2023,
        "fiscalQuarter": 1,
        "fiscalYear": 2023,
        "quarter": "Q1 2023",
        "reportDate": "2023-03-31"
      },
      "analyzedSuccessfully": true
    }
  ],
  "totalFetched": 12,
  "successfulAnalyses": 11,
  "lastUpdated": "2026-01-21T19:50:29.128Z"
}